A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL Patients
This clinical trial, sponsored by the Chinese PLA General Hospital, aims to evaluate the efficacy and safety of chidamide as a bridging therapy in CAR-T treated patients with recurrent or refractory B-cell NHL. The study targets a significant unmet need in the oncology market, particularly for patients exhibiting low NOXA expression, which is associated with CAR-T resistance. The competitive landscape includes existing CAR-T therapies, but the integration of chidamide may provide a differentiated approach to enhance treatment outcomes. Given the increasing prevalence of NHL and the growing adoption of CAR-T therapies, successful results could position the sponsor favorably within the expanding biopharmaceutical market focused on hematologic malignancies.
Indication: Non Hodgkin's Lymphoma
Modality: small molecule
Target: NOXA protein expression modulation via histone deacetylase inhibition (HDACi) to enhance CAR-T cell efficacy in B-cell non-Hodgkin's lymphoma (NHL).
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: NOXA protein expression modulation via histone deacetylase inhibition (HDACi) to enhance CAR-T cell efficacy in B-cell non-Hodgkin's lymphoma (NHL).
View original source fields
Condition raw: Non Hodgkin's Lymphoma
Condition normalized: Non Hodgkin's Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: NOXA protein expression modulation via histone deacetylase inhibition (HDACi) to enhance CAR-T cell efficacy in B-cell non-Hodgkin's lymphoma (NHL).
Target normalized: NOXA protein expression modulation via histone deacetylase inhibition (HDACi) to enhance CAR-T cell efficacy in B-cell non-Hodgkin's lymphoma (NHL).